IGC Pharma, Inc. (IGC) stock
IGCNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 2/3011% above fair value
$0.17−0.00 (-0.57%)
Close on Nov 16, 2026Market cap $18.09MP/E –Yield –
IGC Pharma cash
Cash and short-term investments held at the end of each period.
IGC Pharma's cash was $354.00K at Jun 30, 2026. For fiscal 2026 it was $235.00K, down 42.0% from the year before. Over ten years it grew -16.9% a year on average. The highest annual figure on record is $25.61M in fiscal 2019.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $235.00K | -42.0% |
| FY2025 | Mar 31, 2025 | $405.00K | -66.2% |
| FY2024 | Mar 31, 2024 | $1.20M | -64.2% |
| FY2023 | Mar 31, 2023 | $3.35M | -68.0% |
| FY2022 | Mar 31, 2022 | $10.46M | -28.5% |
| FY2021 | Mar 31, 2021 | $14.63M | +101.5% |
| FY2020 | Mar 31, 2020 | $7.26M | -71.7% |
| FY2019 | Mar 31, 2019 | $25.61M | +1318.1% |
| FY2018 | Mar 31, 2018 | $1.81M | -25.3% |
| FY2017 | Mar 31, 2017 | $2.42M | +62.2% |
| FY2016 | Mar 31, 2016 | $1.49M | +80.8% |
| FY2015 | Mar 31, 2015 | $824.49K | -19.7% |
| FY2014 | Mar 31, 2014 | $1.03M | -3.6% |
| FY2013 | Mar 31, 2013 | $1.06M | +89.1% |
| FY2012 | Mar 31, 2012 | $562.95K | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | $354.00K | -22.0% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $235.00K | -42.0% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | $938.00K | +99.6% |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $1.13M | -26.9% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $454.00K | -75.1% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $405.00K | -66.2% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | $470.00K | -65.9% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $1.55M | -50.5% |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $1.82M | -6.5% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $1.20M | -64.2% |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | $1.38M | -72.6% |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | $3.12M | -54.2% |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | $1.95M | -75.8% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $3.35M | -68.0% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | $5.03M | -57.9% |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | $6.82M | -52.7% |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | $8.05M | -39.5% |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $10.46M | -28.5% |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | $11.94M | +302.3% |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | $14.40M | +187.9% |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | $13.32M | +70.7% |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | $14.63M | +101.5% |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | $2.97M | -80.5% |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | $5.00M | -73.8% |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | $7.80M | -63.8% |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | $7.26M | -71.7% |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | $15.19M | -44.1% |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | $19.10M | +191.4% |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | $21.56M | +1745.4% |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | $25.61M | +1318.1% |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | $27.18M | +1507.4% |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | $6.56M | +998.2% |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | $1.17M | +238.1% |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | $1.81M | -25.3% |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | $1.69M | +127.3% |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | $597.00K | -36.4% |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | $345.61K | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | $2.42M | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | $744.06K | – |
| Q2 FY2017CQ3 2016 | Sep 30, 2016 | $939.29K | – |
See a number that looks wrong?